27 juni 2022
27 juni 2022

Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Do you like it?
Read more
8 september 2021
8 september 2021

Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor

Do you like it?
Read more
19 juli 2021
19 juli 2021

Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives

Do you like it?
Read more
Load more